WO1999062559A1 - Comprimes pharmaceutiques comprenant du cefuroxime axetil - Google Patents
Comprimes pharmaceutiques comprenant du cefuroxime axetil Download PDFInfo
- Publication number
- WO1999062559A1 WO1999062559A1 PCT/CA1999/000446 CA9900446W WO9962559A1 WO 1999062559 A1 WO1999062559 A1 WO 1999062559A1 CA 9900446 W CA9900446 W CA 9900446W WO 9962559 A1 WO9962559 A1 WO 9962559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cefuroxime axetil
- carbonate
- tablet
- bicarbonate
- tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- Cefuroxime axetil is an antibiotic effective against a wide spectrum of microorganisms.
- Antibiotics for oral administration should be in a form which provides high bioavailability, whereby absorption into the bloodstream from the gastro-intestinal tract is maximized.
- Pure cefuroxime axetil can be produced in crystalline form or amorphous form.
- U.S. patent 4820833 discloses that the pure amorphous form is more soluble in water than the pure crystalline form and gives higher bioavailability upon oral administration.
- U.S. patent 4897270 further discloses that film coated tablets comprising cefuroxime axetil (even in amorphous form) give low levels of absorption into the blood stream unless the tablets are formulated such that, when the tablet is ingested, the film coating ruptures very rapidly and the core then disintegrates immediately.
- U.S. patent 5677433 discloses a new ⁇ crystalline form which purports to have good bioavailability characteristics.
- U.S. patents 4820833 and 4897270 teach that good absorption from tablets comprising cefuroxime axetil can be achieved only if the cefuroxime axetil used in the formulation is in pure amorphous form and the tablets contain sufficient disintegrant to cause them to disintegrate immediately in gastro-intestinal fluid.
- Copending Canadian patent application 2,209,868 discloses that the need to use cefuroxime axetil in pure amorphous form can be overcome by making a co-precipitate of cefuroxime axetil and a water-soluble excipient.
- prior art tablets have required inclusion of a relatively large amount of disintegrant to cause the tablets to disintegrate sufficiently rapidly to enable satisfactory absorption after ingestion.
- the disintegrant is an ingredient which absorbs water and swells to cause the tablet to disintegrate when immersed in gastro-intestinal fluid.
- Preferred disintegrants are water-insoluble cross-linked polymers, including, for example, croscarmellose sodium, sodium starch glycolate, and crospovidone.
- the carbonate and bicarbonate that may be used within the scope of the invention may be any carbonate or bicarbonate that is sufficiently non-toxic to be suitable for use as a pharmaceutical excipient, including for example sodium bicarbonate, sodium carbonate, calcium carbonate, potassium carbonate, and magnesium carbonate.
- Preferred carbonates and bicarbonates are sodium bicarbonate, sodium carbonate and calcium carbonate.
- Gastric fluid is acidic.
- the acid in the gastric fluid will react with the carbonate or bicarbonate.
- the reaction causes release of carbon dioxide, and thus effervescence.
- compositions within the scope of the present invention are thus pharmaceutical tablets that comprise cefuroxime axetil and a carbonate or bicarbonate.
- each tablet contained of about 627 mg of cefuroxime axetil, which in turn is equivalent to about 500 mg of cefuroxime.
- the tablets were also tested for dissolution as set out in the United States Pharmacoepia, 23rd edition, page 316.
- the result was over 75% in 45 minutes, which exceeds the lower limit set in the United States Pharmacoepia, and is sufficient to ensure good absorption.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des comprimés pharmaceutiques comprenant du cefuroxime axetil et un carbonate ou un bicarbonate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU38074/99A AU3807499A (en) | 1998-05-29 | 1999-05-18 | Pharmaceutical tablets comprising cefuroxime axetil |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,239,331 | 1998-05-29 | ||
CA 2239331 CA2239331C (fr) | 1998-05-29 | 1998-05-29 | Comprimes pharmaceutiques a base de cefuroxime axetil |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999062559A1 true WO1999062559A1 (fr) | 1999-12-09 |
Family
ID=4162505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/000446 WO1999062559A1 (fr) | 1998-05-29 | 1999-05-18 | Comprimes pharmaceutiques comprenant du cefuroxime axetil |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3807499A (fr) |
CA (1) | CA2239331C (fr) |
WO (1) | WO1999062559A1 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000030647A1 (fr) * | 1998-11-26 | 2000-06-02 | Biochemie Gesellschaft M.B.H. | Compositions contenant du cefuroxime axetil |
EP1342470A1 (fr) * | 2002-03-04 | 2003-09-10 | Pharmathen S.A. | Compositions à libération rapide de Cefuroxime Axetil |
WO2005002540A2 (fr) * | 2003-07-01 | 2005-01-13 | Ranbaxy Laboratories Limited | Compositions de cefuroxime axetil sous forme de suspensions pharmaceutiques pulverulentes seches |
WO2005018618A1 (fr) * | 2003-08-23 | 2005-03-03 | Korea United Pharm, Inc | Preparation d'un comprime stable a l'absorption de l'humidite et a dissolution rapide contenant du cefuroxime axetil et procede de fabrication correspondant |
WO2005067895A1 (fr) * | 2004-01-16 | 2005-07-28 | Sandoz Ag | Compositions pharmaceutiques a liberation controlee |
CN104230957A (zh) * | 2013-06-09 | 2014-12-24 | 广东立国制药有限公司 | 头孢呋辛酸的制备方法及该过程中去除dcc内酯的方法 |
CN106109433A (zh) * | 2016-08-10 | 2016-11-16 | 瑞阳制药有限公司 | 头孢呋辛酯薄膜衣片及其制备方法 |
CN114191375A (zh) * | 2021-12-20 | 2022-03-18 | 广东金城金素制药有限公司 | 一种注射用头孢呋辛钠及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2126479A (en) * | 1982-09-10 | 1984-03-28 | Glaxo Group Ltd | Pharmaceutical-compositions in inert carbon dioxide atmosphere |
US4820833A (en) * | 1982-07-30 | 1989-04-11 | Glaxo Group Limited | Preparation of a highly pure, substantially amorphous form of cefuroxime axetil |
US4897270A (en) * | 1985-09-30 | 1990-01-30 | Glaxo Group Limited | Pharmaceutical compositions |
WO1999008683A1 (fr) * | 1997-08-15 | 1999-02-25 | Bernard Charles Sherman | Compositions pharmaceutiques contenant un cefuroxime axetil |
-
1998
- 1998-05-29 CA CA 2239331 patent/CA2239331C/fr not_active Expired - Fee Related
-
1999
- 1999-05-18 AU AU38074/99A patent/AU3807499A/en not_active Abandoned
- 1999-05-18 WO PCT/CA1999/000446 patent/WO1999062559A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4820833A (en) * | 1982-07-30 | 1989-04-11 | Glaxo Group Limited | Preparation of a highly pure, substantially amorphous form of cefuroxime axetil |
GB2126479A (en) * | 1982-09-10 | 1984-03-28 | Glaxo Group Ltd | Pharmaceutical-compositions in inert carbon dioxide atmosphere |
US4897270A (en) * | 1985-09-30 | 1990-01-30 | Glaxo Group Limited | Pharmaceutical compositions |
WO1999008683A1 (fr) * | 1997-08-15 | 1999-02-25 | Bernard Charles Sherman | Compositions pharmaceutiques contenant un cefuroxime axetil |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000030647A1 (fr) * | 1998-11-26 | 2000-06-02 | Biochemie Gesellschaft M.B.H. | Compositions contenant du cefuroxime axetil |
US6727243B1 (en) | 1998-11-26 | 2004-04-27 | Biochemie Gesellschaft M.B.H. | Compositions comprising cefuroxime axetil |
EP1342470A1 (fr) * | 2002-03-04 | 2003-09-10 | Pharmathen S.A. | Compositions à libération rapide de Cefuroxime Axetil |
WO2005002540A2 (fr) * | 2003-07-01 | 2005-01-13 | Ranbaxy Laboratories Limited | Compositions de cefuroxime axetil sous forme de suspensions pharmaceutiques pulverulentes seches |
WO2005002540A3 (fr) * | 2003-07-01 | 2005-02-17 | Ranbaxy Lab Ltd | Compositions de cefuroxime axetil sous forme de suspensions pharmaceutiques pulverulentes seches |
WO2005018618A1 (fr) * | 2003-08-23 | 2005-03-03 | Korea United Pharm, Inc | Preparation d'un comprime stable a l'absorption de l'humidite et a dissolution rapide contenant du cefuroxime axetil et procede de fabrication correspondant |
WO2005067895A1 (fr) * | 2004-01-16 | 2005-07-28 | Sandoz Ag | Compositions pharmaceutiques a liberation controlee |
CN104230957A (zh) * | 2013-06-09 | 2014-12-24 | 广东立国制药有限公司 | 头孢呋辛酸的制备方法及该过程中去除dcc内酯的方法 |
CN104230957B (zh) * | 2013-06-09 | 2017-02-08 | 广东立国制药有限公司 | 头孢呋辛酸的制备方法及该过程中去除dcc内酯的方法 |
CN106109433A (zh) * | 2016-08-10 | 2016-11-16 | 瑞阳制药有限公司 | 头孢呋辛酯薄膜衣片及其制备方法 |
CN114191375A (zh) * | 2021-12-20 | 2022-03-18 | 广东金城金素制药有限公司 | 一种注射用头孢呋辛钠及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU3807499A (en) | 1999-12-20 |
CA2239331C (fr) | 1999-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5256699A (en) | Dispersible tablet formulation of diclofenac acid free base | |
US5064656A (en) | Uncoated pharmaceutical reaction tablet | |
US4755385A (en) | Oral pharmaceutical preparations containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin | |
AU639137B2 (en) | Superior tasting pharmaceutical composition having porous particles and the process of preparing such pharmaceutical composition | |
EP0250023B1 (fr) | Forme de dosage de la nitrofurantoine | |
CA2000763C (fr) | Produit dispersant | |
CA2182004C (fr) | Comprimes enrobes de paracetamol et de domperidone | |
GB2105590A (en) | Flotable controlled release preparations | |
US3865935A (en) | Tableting of erythromycin base | |
AU2020213378A1 (en) | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof | |
CA2239331C (fr) | Comprimes pharmaceutiques a base de cefuroxime axetil | |
EP1429748B1 (fr) | Compositions solides comprenant du ramipril | |
US5456925A (en) | Pharmaceutical compositions containing furan derivatives | |
EP1684728B1 (fr) | Forme non effervescente de naproxene de sodium comprenant du bicarbonate de soude | |
EP0121901B1 (fr) | Pastilles à libération contrôlée indépendante du PH | |
US6485744B1 (en) | Stabilized cefuroxime axetil | |
CA1108992A (fr) | Composition pharmaceutique contenant du 1,3-bis(2- carboxychromone-5-yloxy)2-hydroxypropane | |
CA2071262C (fr) | Formes posologiques stabilisees de solides de compositions de salicylatede carboxymethylcellulose metallique de choline | |
US5281421A (en) | Gemfibrozil formulations | |
CA2049817A1 (fr) | Formulations de gemfibrozil | |
RU2200558C1 (ru) | Лекарственное средство, содержащее финастерид | |
AU2002325125A1 (en) | Solid compositions comprising ramipril | |
MXPA96004298A (en) | Solid dose forms containing bism | |
WO2003063867A1 (fr) | Comprimes stables exempts de saccharides, comprenant un sel de quinapril ou de moexipril |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09701076 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |